The Effects of Metabolism Tracker Device (Lumen) Usage on Metabolic Control in Adults with Prediabetes: Pilot Clinical Trial

Obes Facts. 2023;16(1):53-61. doi: 10.1159/000527227. Epub 2022 Oct 4.

Abstract

Introduction: Prediabetes is a risk factor for type 2 diabetes mellitus (T2DM). However, it may be reversed via lifestyle changes. Lumen is a novel handheld device that measures exhaled CO2 producing results in agreement with those of indirect calorimetry when assessing metabolic fuel usage. The aim of this study was to examine the effects of following Lumen's personalized, measurement-guided lifestyle intervention program on anthropometric and metabolic variables in adults with prediabetes.

Methods: A 12-week single-arm intervention study was conducted in 27 participants. Body composition and blood markers were measured at the start and end of the study. Each participant took a daily morning (fasted) measurement and received feedback on their metabolic state (i.e., their degree of fat vs. carbohydrate oxidation). Participants were then provided with personalized daily guidelines for their carbohydrate, fat, and protein consumption, along with recommended lifestyle changes.

Results: Intention-to-treat analysis revealed a significant decrease in body weight (5.99 kg, p < 0.001), comprising a significant reduction in percentage body fat (2.93%, p < 0.001) and waist circumference (6.23 cm, p < 0.001). Significant reductions were also observed in glycated hemoglobin A1c (0.27%, p < 0.001), triglycerides (0.45 mg/dL, p < 0.001), and systolic blood pressure (0.5 mm Hg, p < 0.05).

Conclusion: In a 12-week pilot study of participants with prediabetes, Lumen usage significantly improved multiple metabolic parameters, demonstrating its potential to deliver better clinical outcomes for patients with T2DM and metabolic syndrome.

Keywords: Diabetes prevention; Lifestyle intervention; Prediabetes; Weight loss.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Blood Glucose
  • Body Weight
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / therapy
  • Glycated Hemoglobin
  • Humans
  • Pilot Projects
  • Prediabetic State* / therapy

Substances

  • Blood Glucose
  • Glycated Hemoglobin

Grants and funding

The research was funded by Metaflow Ltd. The study was initiated by the staff of the Institute of Endocrinology and Diabetes at Tel Aviv Medical Center after familiarization with Lumen's product in search of new methods to increase compliance to lifestyle changes among obese and prediabetic people.